[Skip to Content]
[Skip to Content Landing]
Viewpoint
March NaN, 2015

Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity

Author Affiliations
  • 1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
  • 2Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
JAMA. 2015;313(12):1213-1214. doi:10.1001/jama.2015.1617

In September 2014, a proprietary formulation of naltrexone extended-release (ER) plus bupropion-ER (brand name Contrave) was approved by the US Food and Drug Administration (FDA),1 becoming the fourth medication approved for long-term weight management in patients with obesity.2 Liraglutide (brand name Saxenda), a glucagon-like peptide 1 receptor agonist, was also approved for obesity treatment in December 2014. This Viewpoint discusses naltrexone-bupropion ER and its potential use for the adjunctive treatment of patients with obesity.

First Page Preview View Large
First page PDF preview
First page PDF preview
×